SCHEMBL6346648

SCHEMBL6346648

CC(=O)OC(C)CCCCn1c(=O)c(N=O)c(N)n(C)c1=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CASP6 P55212 1/20 0.36
▸ ALDH1A1 P00352 2/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ LMNA P02545 2/20 0.32
▸ SMN1; SMN2 Q16637 2/20 0.32
▸ HTT P42858 1/20 0.32
▸ CCR6 P51684 1/20 0.32
▸ HDAC1 Q13547 1/20 0.31
▸ USP2 O75604 1/20 0.31
▸ TNF P01375 1/20 0.31
▸ CYP1A2 P05177 1/20 0.31
▸ TSHR P16473 1/20 0.31
▸ NFKB1 P19838 1/20 0.31
▸ ACHE P22303 1/20 0.31
▸ PDE4A P27815 1/20 0.31
▸ ADORA2B P29275 1/20 0.31
▸ PMP22 Q01453 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6346646 1.00 CASP6 (0.36) CASP6ALDH1A1KMT2AMEN1MAPT
SCHEMBL6356080 0.85 LMNA (0.34) ALDH1A1KMT2AMAPTLMNASMN1; SMN2
SCHEMBL6356082 0.85 LMNA (0.34) ALDH1A1KMT2AMAPTLMNASMN1; SMN2
SCHEMBL6284276 0.75 HPGD (0.42) ALDH1A1MAPTHPGDLMNASMN1; SMN2
SCHEMBL6284279 0.75 HPGD (0.42) ALDH1A1MAPTHPGDLMNASMN1; SMN2
SCHEMBL6346617 0.73 TNF (0.58) ALDH1A1MAPTHPGDLMNASMN1; SMN2
SCHEMBL6346624 0.73 TNF (0.58) ALDH1A1MAPTHPGDLMNASMN1; SMN2
SCHEMBL6346603 0.72 TNF (0.37) MAPTLMNASMN1; SMN2USP2TNF
SCHEMBL6346602 0.72 TNF (0.37) MAPTLMNASMN1; SMN2USP2TNF
SCHEMBL6358828 0.72 ADORA2A (0.43) MAPTLMNASMN1; SMN2USP2TNF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1171442-B1 XANTHINE DERIVATIVES AND ANALOGS AS CELL SIGNALLING INHIBITORS CELL THERAPEUTICS INC (US) 2005-12-07 — — EP disclosed
US-6878715-B1 Therapeutic compounds for inhibiting interleukin-12 signals and method for using same CELL THERAPEUTICS, INC. (US) 2005-04-12 — — US disclosed
US-20050049262-A1 Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same CELL THERAPEUTICS, INC. (US) 2005-03-03 — — US disclosed
EP-1171442-A1 XANTHINE DERIVATIVES AND ANALOGS AS CELL SIGNALLING INHIBITORS CELL THERAPEUTICS, INC. (US) 2002-01-16 — — EP disclosed
WO-2000061583-A1 XANTHINE DERIVATIVES AND ANALOGS AS CELL SIGNALING INHIBITORS CELL THERAPEUTICS, INC. (US) 2000-10-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049262-A1 Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same IL2, CCR10, CCR1 CASP6 407/4885ALDH1A1 1906/4885KMT2A 3982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback